Protara Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File Number: 001-36694 Protara Therapeutics, Inc.(Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 8, 2026 there were 56,204,237 shares of the registrant’s common stock, par value $0.001 per share, outstanding. TABLE OF CONTENTS Page PART I – FINANCIAL INFORMATION1Item 1.Condensed Consolidated Financial Statements1Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (unaudited)1Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March31, 2026 and 2025 (unaudited)2Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three Months Ended March 31,2026 and 2025 (unaudited)3Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(unaudited)4Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk25Item 4.Controls and Procedures25PART II – OTHER INFORMATION26Item 1.Legal Proceedings26Item 1A.Risk Factors26Item 2.Unregistered Sales of Equity Securities and Use of Proceeds26Item 3.Defaults Upon Senior Securities26Item 4.Mine Safety Disclosures26Item 5.Other Information26Item 6.Exhibits27EXHIBIT INDEX27SIGNATURES28 CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Actof 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and aresubject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statementsreflect our current views with respect to, among other things, our operations and financial performance. All statements other thanstatements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. You can generallyidentify these forward-looking statements by terminology such as “believes,” “expects,” “potential,” “continues,” “may,” “will,”“should,” “seek,” “approximately,” “predict,” “intend,” “plans,” “estimates,” “anticipates” or the negative version of these terms orother comparable terminology. Forward-looking statements inherently involve many risks and uncertainties that could cause actualresults to differ from those expressed in forward-looking statements. Forward-looking statements are based on management’s currentplans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that anyexpectation or belief will result or will be achieved or accomplished. Investors therefore should not place undue reliance on forward-looking statements. These forward-looking statements include, but are not limited to, statements about: ●estimates regarding our financial performance, including future revenue, expenses and capital requirements;●our expected cash position and ability to obtain financing in the future on satisfactory terms or at all;●expectations regarding our plans to research, develop and commercialize our current and future product